IDAC Theranostics, Inc.

Innovative research and development for new drugs for intractable diseases centered on cancer

As one of the innovative drug discovery, we are developing anti-CD4 antibody as a therapeutic drug for solid tumors. Discussions are underway to confirm safety in clinical trials and find partner companies to continue research and development.

Establishment Date
April 2012
Drug development
CEO and COO Satoshi Ito

Point of KII view

With the new idea of removing CD4 positive cells, we hope that it will be launched as a new cancer immunotherapeutic drug.

KII growth support

Financing lead, recruitment support for management department managers, candidate selection and negotiation support for business partners